Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Vatalanib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by stopping blood flow to the tumor. Octreotide may help control
symptoms, such as diarrhea, caused by the tumor. Giving vatalanib together with octreotide
may be an effective treatment for neuroendocrine tumors.
PURPOSE: This phase II trial is studying how well giving vatalanib together with octreotide
works in treating patients with progressive neuroendocrine tumors.